Verona Pharma to Present at Jefferies Healthcare Conference
25 mai 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a...
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
09 mai 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Announces May 2022 Investor Conference Participation
04 mai 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: ...
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
03 mai 2022 02h00 HE
|
Verona Pharma plc
Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
19 avr. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
James Brady Joins Verona Pharma as Non-Executive Director
14 mars 2022 03h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
03 mars 2022 02h00 HE
|
Verona Pharma plc
Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona...
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
17 févr. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
24 janv. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
05 janv. 2022 02h00 HE
|
Verona Pharma plc
ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE...